The Impact of RFID: Enhancing Medication Management

Potential import taxes on pharma goods entering the United States continue to have effects on the industry in more ways than one.

Alice Valder Curran outlines the steps manufacturers should take to better prepare for upcoming executive actions on drug pricing and market access.

This serialization system represents a business imperative that yields significant competitive advantages.

Claire Riches highlights inefficiencies in the current drug approval process, while outlining the role of payers and insurers in shifting toward data-driven approval framework.

Addressing drug shortages requires the industry to embrace innovative advanced manufacturing processes underpinned by real-time data.

In a Q&A with Pharma Commerce, Kurt Lunkwitz, ProRx Pharma’s COO, uncovers the stringent requirements that 503B outsourcing facilities must abide by under the Drug Quality and Security Act, while also shedding light on the FDA’s impact when it comes to improving the safety, quality, and trust in compounded drugs.